JP7170031B2 - 生物学的に活性な分子を持続送達するためのミネラルコーティングされたマイクロ粒子 - Google Patents

生物学的に活性な分子を持続送達するためのミネラルコーティングされたマイクロ粒子 Download PDF

Info

Publication number
JP7170031B2
JP7170031B2 JP2020502549A JP2020502549A JP7170031B2 JP 7170031 B2 JP7170031 B2 JP 7170031B2 JP 2020502549 A JP2020502549 A JP 2020502549A JP 2020502549 A JP2020502549 A JP 2020502549A JP 7170031 B2 JP7170031 B2 JP 7170031B2
Authority
JP
Japan
Prior art keywords
mineral
active agent
formulation
coated microparticles
antagonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020502549A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020513033A (ja
JP2020513033A5 (enExample
Inventor
ウィリアム・マーフィー
アナ・クレメンツ
コニー・チェンバレン
レイ・バンダービー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wisconsin Alumni Research Foundation
Original Assignee
Wisconsin Alumni Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wisconsin Alumni Research Foundation filed Critical Wisconsin Alumni Research Foundation
Publication of JP2020513033A publication Critical patent/JP2020513033A/ja
Publication of JP2020513033A5 publication Critical patent/JP2020513033A5/ja
Application granted granted Critical
Publication of JP7170031B2 publication Critical patent/JP7170031B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Ceramic Engineering (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2020502549A 2017-04-03 2018-04-03 生物学的に活性な分子を持続送達するためのミネラルコーティングされたマイクロ粒子 Active JP7170031B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762480710P 2017-04-03 2017-04-03
US62/480,710 2017-04-03
PCT/US2018/025913 WO2018187344A1 (en) 2017-04-03 2018-04-03 Mineral coated microparticles for sustained delivery of biologically active molecules

Publications (3)

Publication Number Publication Date
JP2020513033A JP2020513033A (ja) 2020-04-30
JP2020513033A5 JP2020513033A5 (enExample) 2021-05-13
JP7170031B2 true JP7170031B2 (ja) 2022-11-11

Family

ID=63712804

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020502549A Active JP7170031B2 (ja) 2017-04-03 2018-04-03 生物学的に活性な分子を持続送達するためのミネラルコーティングされたマイクロ粒子

Country Status (10)

Country Link
US (1) US12465654B2 (enExample)
EP (1) EP3606512A4 (enExample)
JP (1) JP7170031B2 (enExample)
KR (1) KR20190130643A (enExample)
CN (1) CN110691588A (enExample)
AU (1) AU2018249816B2 (enExample)
BR (1) BR112019020373A2 (enExample)
CA (1) CA3058802A1 (enExample)
IL (1) IL269607A (enExample)
WO (1) WO2018187344A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3606512A4 (en) 2017-04-03 2021-01-13 Wisconsin Alumni Research Foundation MINERAL COATED MICROPARTICLES INTENDED FOR THE PROLONGED DELIVERY OF BIOLOGICALLY ACTIVE MOLECULES
WO2022051247A1 (en) * 2020-09-01 2022-03-10 Dianomi Therapeutics, Inc. Methods for treating or preventing inflammatory events
DE102020129648A1 (de) * 2020-11-10 2022-05-12 Leopold MTX GmbH Pharmazeutische zusammensetzung
CN114917364A (zh) * 2022-05-12 2022-08-19 云南大学附属医院 一种携IL-8和Anakinra双配体靶向纳米微泡的制备方法
WO2024102801A2 (en) * 2022-11-09 2024-05-16 Wisconsin Alumni Research Foundation Mineral-coated iron oxide microparticles and use of same including use for immunomodulation

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011508788A (ja) 2008-04-18 2011-03-17 ウォーソー・オーソペディック・インコーポレーテッド 疼痛および炎症を軽減、予防もしくは治療するための異なる放出プロフィールをもつ薬物デポー剤

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5075222A (en) 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
TWI267378B (en) * 2001-06-08 2006-12-01 Wyeth Corp Calcium phosphate delivery vehicles for osteoinductive proteins
JP2003212756A (ja) * 2002-01-21 2003-07-30 Olympus Optical Co Ltd 薬剤徐放剤
CA2568352C (en) * 2004-06-04 2011-09-13 Regeneron Pharmaceuticals, Inc. Methods of using il-1 antagonists to treat autoinflammatory disease
US7655758B2 (en) * 2004-08-17 2010-02-02 Regeneron Pharmaceuticals, Inc. Stable liquid IL-1 antagonist formulations
US7473678B2 (en) 2004-10-14 2009-01-06 Biomimetic Therapeutics, Inc. Platelet-derived growth factor compositions and methods of use thereof
AU2006290870B2 (en) * 2005-09-14 2013-02-28 Mannkind Corporation Method of drug formulation based on increasing the affinity of active agents for crystalline microparticle surfaces
JPWO2008041704A1 (ja) 2006-10-02 2010-02-04 独立行政法人物質・材料研究機構 徐放性製剤
US20100143439A1 (en) * 2007-04-16 2010-06-10 University Of Toledo Hybrid Biomimetic Particles, Methods of Making Same and Uses Therefor
US20090111763A1 (en) * 2007-10-26 2009-04-30 Celonova Biosciences, Inc. Loadable polymeric particles for bone augmentation and methods of preparing and using the same
CN105688276A (zh) 2008-02-29 2016-06-22 史密夫和内修有限公司 用于生物医学应用的梯度涂层
US20100015049A1 (en) * 2008-07-16 2010-01-21 Warsaw Orthopedic, Inc. Methods and compositions for treating postoperative pain comprising nonsteroidal anti-inflammatory agents
JP2012503673A (ja) * 2008-09-25 2012-02-09 ティッシュ リジェネレーション システムズ インコーポレイテッド ミネラルコーティングされたマイクロスフェア
US20160017368A1 (en) 2013-02-19 2016-01-21 Wisconsin Alumni Research Foundation Inorganic coatings for the enhancement of chemical transfection
WO2016141242A1 (en) 2015-03-03 2016-09-09 Tissue Regeneration Systems, Inc. Coating scaffolds
US10780054B2 (en) 2015-04-17 2020-09-22 Curevac Real Estate Gmbh Lyophilization of RNA
EP3606512A4 (en) 2017-04-03 2021-01-13 Wisconsin Alumni Research Foundation MINERAL COATED MICROPARTICLES INTENDED FOR THE PROLONGED DELIVERY OF BIOLOGICALLY ACTIVE MOLECULES
JP2020526515A (ja) 2017-07-05 2020-08-31 ウィスコンシン・アルムナイ・リサーチ・ファウンデーションＷｉｓｃｏｎｓｉｎ Ａｌｕｍｎｉ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ 遺伝子送達成果を改善する核酸と抗炎症性分子の共送達のためのミネラルコーティングされたマイクロ粒子
US11628227B2 (en) 2017-07-05 2023-04-18 Wisconsin Alumni Research Foundation Mineral coated microparticles for gene delivery in chronic wound therapy
EP3556728A1 (en) 2018-04-16 2019-10-23 Croda Denmark A/S Organically modified mineral micro-particles, methods of preparing the same and uses thereof
US20190358344A1 (en) 2018-05-23 2019-11-28 Dianomi Therapeutics, Inc. Mineral coated microparticles for sustained delivery of steroids
WO2023086816A1 (en) 2021-11-09 2023-05-19 Wisconsin Alumni Research Foundation Mineral-coated substrates for stabilization of rna-based therapeutic compositions

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011508788A (ja) 2008-04-18 2011-03-17 ウォーソー・オーソペディック・インコーポレーテッド 疼痛および炎症を軽減、予防もしくは治療するための異なる放出プロフィールをもつ薬物デポー剤

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
YU, X. et al.，Adv Funct Mater，2014年，Vol. 24, No. 2，pp. 3082-3093

Also Published As

Publication number Publication date
IL269607A (en) 2019-11-28
JP2020513033A (ja) 2020-04-30
WO2018187344A1 (en) 2018-10-11
CA3058802A1 (en) 2018-10-11
EP3606512A4 (en) 2021-01-13
EP3606512A1 (en) 2020-02-12
BR112019020373A2 (pt) 2020-04-28
KR20190130643A (ko) 2019-11-22
AU2018249816A1 (en) 2019-10-17
US12465654B2 (en) 2025-11-11
US20200164087A1 (en) 2020-05-28
CN110691588A (zh) 2020-01-14
AU2018249816B2 (en) 2025-04-17

Similar Documents

Publication Publication Date Title
JP7170031B2 (ja) 生物学的に活性な分子を持続送達するためのミネラルコーティングされたマイクロ粒子
Gao et al. Hydrogel–metal-organic-framework hybrids mediated efficient oral delivery of siRNA for the treatment of ulcerative colitis
JP2020189878A (ja) 抗炎症剤としてのｐｒｇ４の使用
JP6876608B2 (ja) 可溶性生体分子の生物学的活性を阻害するための組成物及び方法
Afsar et al. The future of IL-1 targeting in kidney disease
KR20190053206A (ko) 혈소판 조성물 및 치료제의 전달 방법
US11779542B2 (en) Mineral coated microparticles for co-delivery of anti-inflammatory molecules with nucleic acids to improve gene delivery outcomes
AU2014372566B2 (en) Uses of oligouronates in cancer treatment
JP2016511747A (ja) ナノ粒子表面結合に基づく薬物の組織への送達
WO2019213686A1 (en) Therapeutic compositions and uses therefor
Schweizer et al. Pharmacokinetics, biocompatibility and bioavailability of a controlled release monoclonal antibody formulation
KR101338516B1 (ko) 다기능성 나노입자를 포함하는 류마티스 관절염 치료용 조성물
US12371501B2 (en) Extended local release of anti-CSFR1 antibodies
HK40014557A (en) Mineral coated microparticles for sustained delivery of biologically active molecules
WO2022051247A1 (en) Methods for treating or preventing inflammatory events
Ubhe IL-1 receptor antagonist: etiological and drug delivery systems overview
Na et al. Formulation and evaluation of VCAM-1-Targeted methotrexate lipid nanoparticles for rheumatoid arthritis therapy
Lavi et al. Sustained release of IL‐1Ra from biodegradable microspheres prolongs its IL‐1‐neutralizing effects
Xiang et al. Recent Advances in Biomimetic Drug Delivery for Rheumatoid Arthritis Treatment
WO2022146925A1 (en) Extended local release of antibodies
Li et al. Nanoparticles coated with osteoblast-like cell membranes as curcumin delivery vehicles for targeted postmenopausal osteoporosis therapy
US20180353436A1 (en) Compositions for modulated release of proteins and methods of use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210331

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210331

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20211118

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220111

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220401

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220610

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20221025

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20221031

R150 Certificate of patent or registration of utility model

Ref document number: 7170031

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250